Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer TSID 10710Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 March 2022
Dostarlimab with carboplatin and paclitaxel for untreated recurrent or advanced endometrial cancer with high microsatellite stability or mismatch repair proficiency ID6415Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 April 2024
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer [ID6381]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC